BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36555369)

  • 1. The Mystery of EVP4593: Perspectives of the Quinazoline-Derived Compound in the Treatment of Huntington's Disease and Other Human Pathologies.
    Grekhnev DA; Kruchinina AA; Vigont VA; Kaznacheyeva EV
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced Store-Operated Calcium Entry Leads to Striatal Synaptic Loss in a Huntington's Disease Mouse Model.
    Wu J; Ryskamp DA; Liang X; Egorova P; Zakharova O; Hung G; Bezprozvanny I
    J Neurosci; 2016 Jan; 36(1):125-41. PubMed ID: 26740655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Manifestation of Huntington's disease pathology in human induced pluripotent stem cell-derived neurons.
    Nekrasov ED; Vigont VA; Klyushnikov SA; Lebedeva OS; Vassina EM; Bogomazova AN; Chestkov IV; Semashko TA; Kiseleva E; Suldina LA; Bobrovsky PA; Zimina OA; Ryazantseva MA; Skopin AY; Illarioshkin SN; Kaznacheyeva EV; Lagarkova MA; Kiselev SL
    Mol Neurodegener; 2016 Apr; 11():27. PubMed ID: 27080129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuronal store-operated calcium entry pathway as a novel therapeutic target for Huntington's disease treatment.
    Wu J; Shih HP; Vigont V; Hrdlicka L; Diggins L; Singh C; Mahoney M; Chesworth R; Shapiro G; Zimina O; Chen X; Wu Q; Glushankova L; Ahlijanian M; Koenig G; Mozhayeva GN; Kaznacheyeva E; Bezprozvanny I
    Chem Biol; 2011 Jun; 18(6):777-93. PubMed ID: 21700213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STIM2 Mediates Excessive Store-Operated Calcium Entry in Patient-Specific iPSC-Derived Neurons Modeling a Juvenile Form of Huntington's Disease.
    Vigont VA; Grekhnev DA; Lebedeva OS; Gusev KO; Volovikov EA; Skopin AY; Bogomazova AN; Shuvalova LD; Zubkova OA; Khomyakova EA; Glushankova LN; Klyushnikov SA; Illarioshkin SN; Lagarkova MA; Kaznacheyeva EV
    Front Cell Dev Biol; 2021; 9():625231. PubMed ID: 33604336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis.
    Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J
    Elife; 2021 Apr; 10():. PubMed ID: 33871358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-Specific iPSC-Based Models of Huntington's Disease as a Tool to Study Store-Operated Calcium Entry Drug Targeting.
    Vigont V; Nekrasov E; Shalygin A; Gusev K; Klushnikov S; Illarioshkin S; Lagarkova M; Kiselev SL; Kaznacheyeva E
    Front Pharmacol; 2018; 9():696. PubMed ID: 30008670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Huntington's disease: cellular and molecular basis of pathology].
    Korzhova VV; Artamonov DN; Vlasova OL; Bezprozvannyĭ IB
    Zh Vyssh Nerv Deiat Im I P Pavlova; 2014; 64(4):359-75. PubMed ID: 25723022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced Expression of Foxp1 as a Contributing Factor in Huntington's Disease.
    Louis Sam Titus ASC; Yusuff T; Cassar M; Thomas E; Kretzschmar D; D'Mello SR
    J Neurosci; 2017 Jul; 37(27):6575-6587. PubMed ID: 28550168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Xyloketal-derived small molecules show protective effect by decreasing mutant Huntingtin protein aggregates in Caenorhabditis elegans model of Huntington's disease.
    Zeng Y; Guo W; Xu G; Wang Q; Feng L; Long S; Liang F; Huang Y; Lu X; Li S; Zhou J; Burgunder JM; Pang J; Pei Z
    Drug Des Devel Ther; 2016; 10():1443-51. PubMed ID: 27110099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor.
    Eddings CR; Arbez N; Akimov S; Geva M; Hayden MR; Ross CA
    Neurobiol Dis; 2019 Sep; 129():118-129. PubMed ID: 31108174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of 4-
    Krishnathas R; Bonke E; Dröse S; Zickermann V; Nasiri HR
    Medchemcomm; 2017 Mar; 8(3):657-661. PubMed ID: 30108783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of huntingtin function slows synaptic vesicle endocytosis in striatal neurons from the htt
    McAdam RL; Morton A; Gordon SL; Alterman JF; Khvorova A; Cousin MA; Smillie KJ
    Neurobiol Dis; 2020 Feb; 134():104637. PubMed ID: 31614197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitophagy in Huntington's disease.
    Šonský I; Vodička P; Vodičková Kepková K; Hansíková H
    Neurochem Int; 2021 Oct; 149():105147. PubMed ID: 34329735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonist of neuronal store-operated calcium entry exerts beneficial effects in neurons expressing PSEN1ΔE9 mutant linked to familial Alzheimer disease.
    Chernyuk D; Zernov N; Kabirova M; Bezprozvanny I; Popugaeva E
    Neuroscience; 2019 Jul; 410():118-127. PubMed ID: 31055008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcium dysregulation and compensation in cortical pyramidal neurons of the R6/2 mouse model of Huntington's disease.
    Oikonomou KD; Donzis EJ; Bui MTN; Cepeda C; Levine MS
    J Neurophysiol; 2021 Oct; 126(4):1159-1171. PubMed ID: 34469694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
    Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
    Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Both Orai1 and TRPC1 are Involved in Excessive Store-Operated Calcium Entry in Striatal Neurons Expressing Mutant Huntingtin Exon 1.
    Vigont V; Kolobkova Y; Skopin A; Zimina O; Zenin V; Glushankova L; Kaznacheyeva E
    Front Physiol; 2015; 6():337. PubMed ID: 26635623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease.
    Valencia A; Reeves PB; Sapp E; Li X; Alexander J; Kegel KB; Chase K; Aronin N; DiFiglia M
    J Neurosci Res; 2010 Jan; 88(1):179-90. PubMed ID: 19642201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXOs modulate proteasome activity in human-induced pluripotent stem cells of Huntington's disease and their derived neural cells.
    Liu Y; Qiao F; Leiferman PC; Ross A; Schlenker EH; Wang H
    Hum Mol Genet; 2017 Nov; 26(22):4416-4428. PubMed ID: 28973411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.